Distinguishing Uterine Leiomyosarcoma from Benign Leiomyoma

Histologic and Cellular Characteristics

The American College of Radiology notes that age and menopausal status are critical risk factors, with leiomyosarcomas comprising 1.7% of women undergoing hysterectomy for presumed fibroids in their seventh decade of life 3, 4
Postmenopausal women with growing uterine masses are at higher risk 5
Rapid tumor growth is a red flag, though this can occur in benign fibroids during pregnancy 3

The American College of Radiology recommends MRI with diffusion-weighted imaging as the most effective preoperative imaging modality for distinguishing leiomyosarcoma from leiomyoma 6, 7
Transvaginal ultrasound is the initial imaging modality with 90-99% sensitivity and 98% specificity for detecting fibroids, but it cannot reliably differentiate leiomyosarcoma from benign leiomyoma on ultrasound alone 5

The gold standard for diagnosis remains histopathologic examination with criteria for malignancy including increased mitotic figures, cellular pleomorphism, and thrombotic/coagulative tumor necrosis 3, 4, 8
Increased mitotic figures, typically >10 mitotic figures per 10 high-power fields, is a key criterion for malignancy 8

The American College of Radiology and the European Society of Medical Oncology recommend avoiding morcellation procedures when malignancy cannot be excluded, as tumor spillage dramatically worsens prognosis if leiomyosarcoma is present 8
En bloc total hysterectomy is the standard treatment when leiomyosarcoma is suspected or confirmed 8

Leiomyosarcomas account for only 0.1 % of all uterine tumors, but they represent ≈ 1.7 % of hysterectomy specimens obtained for presumed fibroids in women in their seventh decade – indicating a very low overall incidence but a modest increase in older women undergoing surgery for fibroids. 9
In post‑menopausal women, especially after age 60, the risk of leiomyosarcoma rises markedly compared with pre‑menopausal women, who can be considered to have benign smooth‑muscle tumors for practical clinical purposes. 9
Approximately 70 % of women have identifiable leiomyomas at menopause, yet malignant transformation of these benign lesions remains exceedingly rare. 10

Comprehensive molecular‑genetic studies demonstrate no progression pathway from benign leiomyoma to leiomyosarcoma; the two entities have distinct origins. 9
About one‑third of leiomyomas exhibit clonal chromosomal aberrations, but the specific genetic alterations differ between individual fibroids even within the same patient, underscoring heterogeneity rather than a shared malignant trajectory. 9
The molecular dysregulation observed in benign fibroids drives disproportionate growth relative to normal myometrium, not malignant potential. 9
Leiomyosarcomas arise through independent pathogenic pathways involving different genetic mutations from those seen in leiomyomas. 9

Permanent (paraffin‑embedded) histopathologic sections are required for definitive diagnosis; intra‑operative frozen sections are unreliable for distinguishing benign from malignant smooth‑muscle tumors. 9
The three cardinal histologic criteria for leiomyosarcoma are:
All three features together support a diagnosis of leiomyosarcoma. 9

Post‑menopausal growth of a uterine mass should raise heightened suspicion for leiomyosarcoma and prompt thorough evaluation. 9
All surgical specimens (regardless of patient age or clinical presentation) must undergo careful pathological examination to exclude occult malignancy. 9
Post‑menopausal patients with existing or enlarging uterine masses warrant closer surveillance compared with pre‑menopausal patients. 9
Central necrosis that occurs during rapid fibroid growth in pregnancy represents a benign degenerative change, not an indication of malignancy. 9